# An Extension to Study AZA PH GL 2003 CL 001 Allowing for Continuation of Azacitidine Treatment in Patients With Myelodysplastic Syndromes (MDS)

> **NCT01186939** · PHASE3 · COMPLETED · sponsor: **Celgene** · enrollment: 40 (actual)

## Conditions studied

- Myelodysplastic Syndromes

## Interventions

- **DRUG:** Azacitidine

## Key facts

- **NCT ID:** NCT01186939
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-04-01
- **Primary completion:** 2009-09-01
- **Final completion:** 2009-09-01
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2019-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01186939

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01186939, "An Extension to Study AZA PH GL 2003 CL 001 Allowing for Continuation of Azacitidine Treatment in Patients With Myelodysplastic Syndromes (MDS)". Retrieved via AI Analytics 2026-09-28 from https://api.ai-analytics.org/clinical/NCT01186939. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*